Literature DB >> 36175488

Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?

Bilal Haj Najeeb1, Ursula Schmidt-Erfurth2.   

Abstract

Given the wide spectrum of unique characteristics of macular neovascularization type 3 (MNV3) compared with types 1 and 2, we suggest regrading the colour photography assessment of the AREDS study to verify the impact of AREDS supplements on eyes with MNV3.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID： 36175488     DOI： 10.1038/s41433-022-02249-2

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


  15 in total

1.  Retinal angiomatous proliferation in age-related macular degeneration.

Authors:  L A Yannuzzi; S Negrão; T Iida; C Carvalho; H Rodriguez-Coleman; J Slakter; K B Freund; J Sorenson; D Orlock; N Borodoker
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Authors:  Ebenezer Daniel; James Shaffer; Gui-shuang Ying; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Maureen G Maguire
Journal:  Ophthalmology       Date:  2015-12-08       Impact factor: 12.079

3.  Incidence and characteristics of neovascularization in fellow eyes of Japanese patients with unilateral retinal angiomatous proliferation.

Authors:  Miki Sawa; Chikaka Ueno; Fumi Gomi; Kohji Nishida
Journal:  Retina       Date:  2014-04       Impact factor: 4.256

4.  INFLUENCE OF FELLOW-EYE EXAMINATION INTERVAL ON VISUAL ACUITY AT FELLOW-EYE NEOVASCULARIZATION IN UNILATERAL TYPE 3 NEOVASCULARIZATION.

Authors:  Jae Hui Kim; Jong Woo Kim; Chul Gu Kim; Dong Won Lee
Journal:  Retina       Date:  2020-07       Impact factor: 4.256

5.  Environmental and genetic risk factors for retinal angiomatous proliferation.

Authors:  Albert Caramoy; Tina Ristau; Yara T Lechanteur; Lebriz Ersoy; Sebastian Müller; Faik Gelisken; Carel B Hoyng; Bernd Kirchhof; Anneke I den Hollander; Sascha Fauser
Journal:  Acta Ophthalmol       Date:  2014-05-22       Impact factor: 3.761

6.  Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.

Authors:  Marcela Marsiglia; Sucharita Boddu; Christine Y Chen; Jesse J Jung; Sarah Mrejen; Roberto Gallego-Pinazo; K Bailey Freund
Journal:  Retina       Date:  2015-05       Impact factor: 4.256

7.  RAP study, report 1: novel subtype of macular neovascularisation type III, cilioretinal MNV3.

Authors:  Bilal Haj Najeeb; Gabor G Deak; Ursula Margarethe Schmidt-Erfurth; Bianca S Gerendas
Journal:  Br J Ophthalmol       Date:  2020-03-11       Impact factor: 4.638

8.  Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation.

Authors:  Nicole E Gross; Alexander Aizman; Allison Brucker; James M Klancnik; Lawrence A Yannuzzi
Journal:  Retina       Date:  2005-09       Impact factor: 4.256

9.  THE RAP STUDY, REPORT TWO: The Regional Distribution of Macular Neovascularization Type 3, a Novel Insight Into Its Etiology.

Authors:  Bilal Haj Najeeb; Gabor Deak; Ursula Schmidt-Erfurth; Bianca S Gerendas
Journal:  Retina       Date:  2020-12       Impact factor: 4.256

Review 10.  CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus.

Authors:  Tien Yin Wong; Paolo Lanzetta; Francesco Bandello; Bora Eldem; Rafael Navarro; Monica Lövestam-Adrian; Anat Loewenstein
Journal:  Retina       Date:  2020-04       Impact factor: 3.975
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.